Urology
Volume 71, Issue 1 , Pages 146-150 , January 2008

Prostatic Acid Phosphatase Adversely Affects Cause-Specific Survival in Patients with Intermediate to High-Risk Prostate Cancer Treated with Brachytherapy

  • L. Christine Fang

      Affiliations

    • Department of Radiation Oncology, University of Washington Medical Center, Seattle, Washington
    • Corresponding Author InformationReprint requests: L. Christine Fang, M.D., Department of Radiation Oncology, University of Washington Medical Center, 1959 Northeast Pacific Street, Box 356043, Seattle, WA 98195.
    • ,
  • Michael Dattoli

      Affiliations

    • Dattoli Cancer Center and Brachytherapy Research Institute, Sarasota, Florida
    • ,
  • Al Taira

      Affiliations

    • Department of Radiation Oncology, University of Washington Medical Center, Seattle, Washington
    • ,
  • Lawrence True

      Affiliations

    • Department of Pathology, University of Washington Medical Center, Seattle, Washington
    • ,
  • Richard Sorace

      Affiliations

    • Dattoli Cancer Center and Brachytherapy Research Institute, Sarasota, Florida
    • ,
  • Kent Wallner

      Affiliations

    • Department of Radiation Oncology, University of Washington Medical Center, Seattle, Washington
    • Department of Radiation Oncology, Puget Sound Health Care System, Department of Veterans Affairs, Seattle, Washington
    • Group Health Cooperative, Seattle, Washington

Received 11 April 2007 ,Accepted 10 August 2007.

References 

  1. Gutman AB, Gutman EB. An “acid” phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest. 1938;17:473–478
  2. Huggins C, Hodges CV. Studies on prostatic cancer (I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate). Cancer Res. 1941;1:293–297
  3. Burnett AL, Chan DW, Brendler CB, et al. The value of serum enzymatic acid phosphatase in the staging of localized prostate cancer. J Urol. 1992;148:1832–1834
  4. Drago JR, Badalament RA, Wientjes MG, et al. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate: Ohio State University experience. Urology. 1989;34:187–192
  5. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991;145:907–923
  6. Bruce AW, Mahan DE, Morales A, et al. An objective look at acid phosphatase determinations: a comparison of biochemical and immunological methods. Br J Urol. 1979;51:213–217
  7. Salo JO, Rannikko S. The value of acid phosphatase measurements in predicting extraprostatic cancer growth before radical prostatectomy. Br J Urol. 1988;62:439–442
  8. Dattoli M, Wallner K, True L, et al. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphatase. Cancer. 2003;97:979–983
  9. Han M, Piantadosi S, Zahurak ML, et al. Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology. 2001;57:707–711
  10. Moul JW, Connelly RR, Perahia B, et al. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. J Urol. 1998;159:935–940
  11. Roy AV, Brower ME, Hayden JE. Sodium thymolphthalein monophosphate: a new acid phosphatase substrate with greater specificity for the prostatic enzyme in serum. Clin Chem. 1971;17:1093–1102
  12. Merrick GS, Butler WM. Modified uniform seed loading for prostate brachytherapy: rationale, design, and evaluation. Tech Urol. 2000;6:78–84
  13. Wallner K, Blasko JC, Dattoli M. Prostate Cancer Made Complicated. Seattle: SmartMedicine Press; 2007;
  14. Mortarelli EA. Prostate specific antigen and prostatic acid phosphatase measurements for the follow-up of patients with prostate cancer. Ann Clin Lab Sci. 1992;22:201–206
  15. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909–916
  16. Roach M, Lu J, Pilepich MV, et al. Long-term survival after radiotherapy alone: Radiation Therapy Oncology Group prostate cancer trials. J Urol. 1999;161:864–868
  17. Carlton JC, Zagars GK, Oswald MJ. The role of serum prostatic acid phosphatase in the management of adenocarcinoma of the prostate with radiotherapy. Int J Radiat Oncol Biol Phys. 1990;19:1383–1388
  18. Johnson DE, Prout GR, Scott WW, et al. Clinical significance of serum acid phosphatase levels in advanced prostatic carcinoma. Urology. 1976;8:123–126
  19. Taira A, Merrick G, Wallner K, et al. Reviving the acid phosphatase test for prostate cancer. Oncology. 2007;21:1003–1110
  20. Zagars GK, von Eschenbach AC, Ayala AG. Prognostic factors in prostate cancer: analysis of 874 patients treated with radiation therapy. Cancer. 1993;72:1709–1725
  21. San Francisco IF, Olumi AF, Yoon JH, et al. Preoperative serum acid phosphatase and alkaline phosphatase are not predictors of pathological stage and prostate-specific antigen failure after radical prostatectomy. BJU Int. 2003;92:924–928
  22. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103–106
  23. D’Amico AV, Schultz D, Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA. 2000;284:1280–1283
  24. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol. 2003;21:3972–3978
  25. D’Amico AV, Manola J, Loffredo M, et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821–827
  26. Potters L, Torre T, Ashley R, et al. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol. 2000;18:1187–1192
  27. Merrick GS, Butler WM, Wallner KE, et al. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam. Int J Radiat Oncol Biol Phys. 2007;68:34–40
  28. Ciezki JP, Klein EA, Angermeier K, et al. A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy. Int J Radiat Oncol Biol Phys. 2004;60:1347–1350

PII: S0090-4295(07)02006-7

doi: 10.1016/j.urology.2007.08.024

Urology
Volume 71, Issue 1 , Pages 146-150 , January 2008

Article Tools

* Image Usage & Resolution